ZENITH — Zilebesiran (RNAi)
Treatment-Resistant Hypertension
Protocol: Alnylam ALN-AGT01-008
About this study
Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, for adults with treatment-resistant hypertension and elevated cardiovascular risk.
Sponsor: Alnylam Pharmaceuticals · Principal Investigator: Dr. William W. O'Neill, MD, FACC (Senior PI)
Key eligibility
- Adults 18+ with treatment-resistant hypertension
- Currently on ≥3 antihypertensive medications
- Elevated cardiovascular risk profile
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.